


## 5 We Claim:

1. A compound having the Formula I



wherein


- 10  $R^1$  is  $-\text{CO}_2\text{CH}_3$  or  $-\text{H}$ ;  
 $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ , wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and  
 $R^3$  is  $-\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$  and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ ; or a pharmaceutically acceptable salt of said  
15 compound with the proviso that  
if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{H}$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ;  
if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , then  $R^2$  is not  $-\text{CH}_2\text{CH}_2$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CH}_2\text{CO}_2\text{H}$ ; and  
20 if  $R^1$  is  $-\text{CO}_2\text{CH}_3$  and  $R^2$  is  $-\text{CH}_2\text{CH}_3$ , then  $R^3$  is not  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ , or  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ .

2. The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CH}_3$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ .  
25
3. The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^3$  is  $-\text{H}$ , and  $R^2$  is selected from  $-\text{CH}_2\text{CO}_2\text{A}$  or  $-\text{CH}_2\text{CH}_2\text{OA}$ .
4. The compound of claim 1 wherein  $R^1$  and  $R^3$  is  $\text{H}$ , and  $R^2$  is selected  
30 from the group consisting of  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $\text{CH}_2\text{CH}_2\text{OA}$ .

5            5.        The compound of claim 1 wherein  $R^1$  is  $-\text{CO}_2\text{CH}_3$ ,  $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  
and  $R^3$  is  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ .

6.        A compound selected from the group consisting of  
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-  
10 trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;  
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-  
trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;  
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-  
carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl  
15 ester;  
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-  
tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;  
[2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-  
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester; and  
20 [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-  
trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid.


7.        A compound of Formula II



25        wherein  $R^5$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{H}$ ,  $-\text{CO}_2\text{A}$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  
 $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CH}_2\text{OA}$ ,  $-\text{CH}_2\text{CH}_2\text{OSO}_3\text{H}$ ,  $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$ ,  $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CO}_2\text{H}$ , and  $-\text{C}(\text{O})\text{N}(\text{H})\text{C}(\text{O})\text{NH}_2$ , and wherein A is 3,4,5-trihydroxy-  
tetrahydropyran-2-carboxylic acid.

30        8.        The compound of claim 7 wherein  $R^5$  is selected from  $-\text{CH}_2\text{CH}_3$  or  
 $-\text{CO}_2\text{H}$ .

- 5            9.        A compound of Formula III



wherein  $R^6$  is  $-\text{CH}_2\text{OA}$ ,  $-\text{C}(\text{O})\text{N}(\text{H})\text{CH}_2\text{CO}_2\text{A}$  and  $-\text{CH}(\text{SO}_3\text{H})\text{N}(\text{H})\text{CO}_2\text{CH}_3$ , and wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid.

10

10.        A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 1 in the mammal.

15

11.        A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound of claim 6 or 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-(2-hydroxy-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in the mammal.

20

12.        A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising monitoring the presence of a compound selected from the group consisting of a compound of claim 7, 2-methyl-6-trifluoromethyl-quinoline, and (6-trifluoromethyl-quinolin-2-yl)methanol in the mammal.

25

30


13.        A method for indicating the presence of or exposure to 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-

5 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising  
 monitoring the presence of a compound selected from the group consisting of  
 3,5-Bis-trifluoromethyl-benzoic acid, 6-(3,5-Bis-trifluoromethyl-benzoyloxy)-3,4,5-  
 trihydroxy-tetrahydro-pyran-2-carboxylic acid, 6-(3,5-Bis-trifluoromethyl-  
 benzyloxy)-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid, (3,5-Bis-  
 10 trifluoromethyl-phenyl)-methoxycarbonylamino-methanesulfonic acid, (3,5-Bis-  
 trifluoromethyl-benzoylamino)-acetic acid, and (3,5-Bis-trifluoromethyl-  
 benzoylamino)- 3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid in the mammal.

14. A method for indicating the presence of or exposure to 4-[(3,5-bis-  
 15 trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl)-6-trifluoromethyl-3,4-  
 dihydro-2H-quinoline-1-carboxylic acid ethyl ester in a mammal comprising  
 monitoring the presence of a compound selected from the group consisting of  
 3,5-bis-trifluoromethylbenzoic acid, 2-methyl-6-trifluoromethyl-quinoline, and  
 6-trifluoromethyl-quinoline-2-carboxylic acid in the mammal.

20

15. A method for treating atherosclerosis comprising administering to a  
 mammal an atherosclerosis treating amount of a compound of Formula I



wherein

25  $R^1$  is  $-\text{CO}_2\text{CH}_3$  or  $-\text{H}$ ;  
 $R^2$  is  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CH}_2\text{CO}_2\text{H}$ ,  $-\text{CH}_2\text{CO}_2\text{A}$ , and  $-\text{CH}_2\text{CH}_2\text{OA}$ , wherein A is 3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; and  
 $R^3$  is  $-\text{H}$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OH}$ ,  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{H}$ ,  
 $-\text{CO}_2\text{CH}_2\text{CH}_2\text{OA}$  and  $-\text{CO}_2\text{CH}_2\text{CO}_2\text{A}$ ; a prodrug thereof, or a pharmaceutically  
 30 acceptable salt of said compound or of said prodrug with the proviso that

- 5           if R<sup>1</sup> is -CO<sub>2</sub>CH<sub>3</sub> and R<sup>3</sup> is -H, then R<sup>2</sup> is not -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, or -CH<sub>2</sub>CO<sub>2</sub>H;
- if R<sup>1</sup> is -CO<sub>2</sub>CH<sub>3</sub> and R<sup>3</sup> is -CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, then R<sup>2</sup> is not -CH<sub>2</sub>CH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, or -CH<sub>2</sub>CO<sub>2</sub>H; and
- if R<sup>1</sup> is -CO<sub>2</sub>CH<sub>3</sub> and R<sup>2</sup> is -CH<sub>2</sub>CH<sub>3</sub>, then R<sup>3</sup> is not -CO<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, or
- 10   -CO<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, or a compound a compound selected from the group consisting of
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxyethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid carboxymethyl ester;
- 15   [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-carboxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
- [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-(2-ethyl-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-carbamic acid methyl ester;
- 20   [2R, 4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-[2-(2-hydroxyethyl)-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl]-carbamic acid methyl ester;
- [2R, 4S] {4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-2-yl}-acetic acid, and
- a prodrug thereof, or a pharmaceutically acceptable amount salt of said compound or
- 25   of said prodrug.